@article{6d978148b74349c899ff4f34432d3ba2,
title = "Remote Ischemic Conditioning: Feasible and Potentially Beneficial for Ischemic Stroke",
author = "Hess, {David C.} and Blauenfeldt, {Rolf A.} and Grethe Andersen",
note = "Funding Information: having a patent with Augusta University and Athersys Inc for stem cells in neurologic diseases and being on the scientific advisory board for Athersys, Inc. Dr Blauenfeldt reported receiving personal fees from Bayer and Novo Nordisk. The authors reported receiving support from the National Institutes of Health (R01 NS099455, Dr Hess; 1UO1NS113356, Dr Hess; R01NS112511, Drs Hess, Blauenfeldt, and Andersen), Vilhelm Petersens Mindelegat, TrygFonden, and the Novo Nordisk Foundation (Dr Andersen).",
year = "2022",
month = aug,
day = "16",
doi = "10.1001/jama.2022.13365",
language = "English (US)",
volume = "328",
pages = "622--624",
journal = "JAMA",
issn = "0098-7484",
publisher = "American Medical Association",
number = "7",
}